Literature DB >> 31078245

Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?

Manasi Agrawal1, Jean-Frederic Colombel2.   

Abstract

Inflammatory bowel diseases, including Crohn disease (CD) and ulcerative colitis (UC), are chronic, progressive, immune-mediated inflammatory diseases of the gastrointestinal tract. Early therapy using a treat-to-target (T2T) approach, which implies identification of a pre-defined target, followed by optimization of therapy and regular monitoring until the goal is achieved is critical in preventing adverse long-term outcomes. In this review, the authors discuss the T2T guidance developed by the Selecting Therapeutic Targets in Inflammatory Bowel Disease committee, new evidence published on the role of various targets in CD and UC, as well as the real-world applicability of T2T."
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Inflammatory bowel diseases; Long-term outcomes; Treat-to-target; Ulcerative colitis

Mesh:

Year:  2019        PMID: 31078245     DOI: 10.1016/j.giec.2019.02.004

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  9 in total

1.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

2.  Disease Clearance in Inflammatory Bowel Disease.

Authors:  Jean-Frédéric Colombel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-05

3.  Assessing Oral Medication Adherence and Identifying Predictors of Low Adherence in Chinese Inflammatory Bowel Disease Patients.

Authors:  Wen Hu; Shurong Hu; Yimiao Zhu; Hanwen Chen; Yan Chen
Journal:  Patient Prefer Adherence       Date:  2020-07-02       Impact factor: 2.711

4.  Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?

Authors:  Olga Maria Nardone; Rosanna Cannatelli; Davide Zardo; Subrata Ghosh; Marietta Iacucci
Journal:  Therap Adv Gastroenterol       Date:  2019-07-18       Impact factor: 4.409

5.  Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.

Authors:  Katia Farias E Silva; Hayandra F Nanini; Cynthia Machado Cascabulho; Siane L B Rosas; Patricia T Santana; Antonio José de V Carneiro; Elias Anaissie; Marcio Nucci; Heitor Siffert Pereira de Souza
Journal:  World J Gastroenterol       Date:  2021-03-07       Impact factor: 5.742

6.  Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD.

Authors:  Elleni J Pippis; Bruce R Yacyshyn
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 5.325

Review 7.  Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis.

Authors:  Paulina Núñez F; Noa Krugliak Cleveland; Rodrigo Quera; David T Rubin
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

8.  Switching TNFα inhibitors: Patterns and determinants.

Authors:  Rosanne W Meijboom; Helga Gardarsdottir; Matthijs L Becker; Mark C H de Groot; Kris L L Movig; Johan Kuijvenhoven; Toine C G Egberts; Hubert G M Leufkens; Thijs J Giezen
Journal:  Pharmacol Res Perspect       Date:  2021-08

9.  Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission.

Authors:  Marietta Iacucci; Louisa Jeffery; Animesh Acharjee; Olga Maria Nardone; Davide Zardo; Samuel C L Smith; Alina Bazarova; Rosanna Cannatelli; Uday N Shivaji; John Williams; Georgios Gkoutos; Subrata Ghosh
Journal:  Inflamm Bowel Dis       Date:  2021-10-20       Impact factor: 5.325

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.